By-Health’s new Hericum Erinaceus & Lactobacillus Reuteri product is based on Pylopass, German biotech firm Organobalance’s proprietary strain which specifically binds and removes carcinogenic stomach bacteria, and lowering the H. pylori load while keeping the natural gut microbiota balance intact.
“We are glad to be collaborating with By-Health who will use Pylopass in their product portfolio,” Professor Christine Lang, microbiologist, founder and managing director of Organobalance, said.
“This gives the Chinese consumers access to an effective and natural way to control the pathogenic stomach bacterium Helicobacter pylori.”
In China, 60-80% of the population are infected with H. pylori, according to By-Health.
“The ratio is much higher than in Western countries, and it is mainly related to the living environment and habits in China,” said Zhang Xuguang, director, By-Health Science and Technology Centre.
“With increasing awareness of health and the popularity of health checks, people are increasingly concerned about the harmful effects of H. pylori.”
The product is positioned as a natural alternative to antibiotic treatment.
Research revealed that resistance against the most commonly used antibiotics for H.pylori treatment has increased from 10-15% in 2000 up to 40-50% in 2014 – lowering the success rate of antibiotic treatments significantly.
Several clinical studies demonstrated that Pylopass reduces the colonisation of H. pylori in the stomach and prevents gastritis and peptic ulcers, said Organobalance.
“New studies show that Pylopass can not only reduce the colonisation of Helicobacter pylori in the stomach, but also improve the symptoms associated with gastritis and increase the efficacy of the pharmaceutical treatment,” Gilles Jequier, Organobalance commercial director, said.
Organobalance works with companies in Asia to develop new health products. Jequier said some of these products are currently available in Malaysia and Vietnam, with new offerings to be launched in Korea and India this year.
“Thanks to our parent company Novozymes, we have a global footprint that allows us to be present in all the major Asian markets,” he added.